Literature DB >> 21735134

Combined survival analysis of cardiac patients by a Cox PH model and a Markov chain.

Michal Shauly1, Gad Rabinowitz, Harel Gilutz, Yisrael Parmet.   

Abstract

The control and treatment of dyslipidemia is a major public health challenge, particularly for patients with coronary heart diseases. In this paper we propose a framework for survival analysis of patients who had a major cardiac event, focusing on assessment of the effect of changing LDL-cholesterol level and statins consumption on survival. This framework includes a Cox PH model and a Markov chain, and combines their results into reinforced conclusions regarding the factors that affect survival time. We prospectively studied 2,277 cardiac patients, and the results show high congruence between the Markov model and the PH model; both evidence that diabetes, history of stroke, peripheral vascular disease and smoking significantly increase hazard rate and reduce survival time. On the other hand, statin consumption is correlated with a lower hazard rate and longer survival time in both models. The role of such a framework in understanding the therapeutic behavior of patients and implementing effective secondary and primary prevention of heart diseases is discussed here. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735134     DOI: 10.1007/s10985-011-9196-y

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  10 in total

1.  The therapeutic gap--compliance with medication and guidelines.

Authors:  J Feely
Journal:  Atherosclerosis       Date:  1999-09-09       Impact factor: 5.162

2.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Authors:  Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Richard C Pasternak; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

3.  Computerized community cholesterol control (4C): meeting the challenge of secondary prevention.

Authors:  Harel Gilutz; Lena Novack; Pesach Shvartzman; Julian Zelingher; Dan Y Bonneh; Yaakov Henkin; Maximo Maislos; Roni Peleg; Zvi Liss; Gad Rabinowitz; Daniel Vardy; Doron Zahger; Reuven Ilia; Niki Leibermann; Avi Porath
Journal:  Isr Med Assoc J       Date:  2009-01       Impact factor: 0.892

4.  Defining and measuring physicians' responses to clinical reminders.

Authors:  Geva Vashitz; Joachim Meyer; Yisrael Parmet; Roni Peleg; Dan Goldfarb; Avi Porath; Harel Gilutz
Journal:  J Biomed Inform       Date:  2008-10-26       Impact factor: 6.317

5.  Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.

Authors:  M H Eckman; H J Levine; D N Salem; S G Pauker
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

6.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

7.  The Markov process in medical prognosis.

Authors:  J R Beck; S G Pauker
Journal:  Med Decis Making       Date:  1983       Impact factor: 2.583

8.  Hemodialysis--projecting future bed needs. Deterministic and probabilistic forecasting.

Authors:  J S Pliskin; T I Steinman; E G Lowrie; C H Beck
Journal:  Comput Biomed Res       Date:  1976-08

9.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleight; Richard Peto
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.